medigraphic.com
Academia Mexicana de Neurología, A.C.

2006, Number 4

<< Back Next >>

Rev Mex Neuroci 2006; 7 (4)

Molecular markers in Alzheimer disease

Campos-Peña V, Meraz RMA

Language: Spanish
References: 37
Page: 293-299
PDF size: 409.24 Kb.


ABSTRACT

Introduction: In the last years, the neurodegenerative diseases have become the main problem of health. They are characterized by the degeneration of specific cellular populations and include diverse types of diseases which contribute of significant way to the morbidity and mortality of the age population. The Alzheimer disease (AD) is the most common dementia, representing 50% the total cases. It is characterized by the presence of neuritic plaques (NP) and neurofibrillary tangles (NFT) and is the result of a multifactor process that implies diverse genes located in different chromosomes, which makes more complex. The research made until the moment, try the search of molecular markers that allow the diagnosis of the disease in early stages allowing with this a better handling for the patient.


REFERENCES

  1. Cacabelos. Alzheimer’s disease. Neuroimmune dysfunction and new forms of therapeutic intervention. Med Clin (Barc) 1994; 102(11): 420-2.

  2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939-44.

  3. Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985; 82(13): 4531-4.

  4. Perry EK, Atack JR, Perry RH, Hardy JA, Dodd PR, Edwardson JA, Blessed G, Tomlinson BE, Fairbairn AF. Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer’s disease and the normal. J Neurochem 1984; 42(5):1402-10.

  5. Heyman A, Wilkinson WE, Hurwitz BJ, Helms MJ, Haynes CS, Utley CM, Gwyther LP. Early-onset Alzheimer’s disease: clinical predictors of institutionalization and death. Neurology 1987; 37(6): 980-4.

  6. Roberts GW, Nash M, Ince PG, Royston MC, Gentleman SM. On the origin of Alzheimer’s disease: a hypothesis. Neuroreport 1993; 4(1): 7-9.

  7. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33(6): 403-8. Review.

  8. Schubert D, LaCorbiere M, Saitoh T, Cole G. Characterization of an amyloid beta precursor protein that binds heparin and contains tyrosine sulfate. Proc Natl Acad Sci USA 1989; 86(6): 2066-9.

  9. Schubert D, Cole G, Saitoh T, Oltersdorf T. Amyloid beta protein precursor is a mitogen. Biochem Biophys Res Commun 1989; 162(1): 83-8.

  10. Crowther RA, Wischik CM. Image reconstruction of the Alzheimer paired helical filament. EMBO J 1985; 4(13B): 3661-5.

  11. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995; 269(5226): 973-7.

  12. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995; 375(6534): 754-60.

  13. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17(5): 1005-13.

  14. Doan A, Thinakaran G, Borchelt DR, Slunt HH, Ratovitsky T, Podlisny M, Selkoe DJ, Seeger M, Gandy SE, Price DL, Sisodia SS. Protein topology of presenilin 1. Neuron 1996; 17(5): 1023-30.

  15. Li X, Greenwald I. Additional evidence for an eight-transmembrane-domain topology for Caenorhabditis elegans and human presenilins. Proc Natl Acad Sci USA 1998; 95(12): 7109-14.

  16. Busciglio J, Hartmann H, Lorenzo A, Wong C, Baumann K, Sommer B, Staufenbiel M, Yankner BA. Neuronal localization of presenilin-1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. J Neurosci 1997; 17(13): 5101-7.

  17. Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe DJ, Haass C. The proteolytic fragments of the Alzheimer’s disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J Biol Chem 1998; 273(6): 3205-11.

  18. Kim SH, Lah JJ, Thinakaran G, Levey A, Sisodia SS. Subcellular localization of presenilins: association with a unique membrane pool in cultured cells. Neurobiol Dis. 2000; 7(2): 99-117.

  19. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398(6727): 518-22.

  20. Pigino G, Pelsman A, Mori H, Busciglio J. Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J Neurosci 2001; 21(3): 834-42.

  21. Kulic L, Walter J, Multhaup G, Teplow DB, Baumeister R, Romig H, Capell A, Steiner H, Haass C. Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch. Proc Natl Acad Sci USA 2000; 97(11): 5913-8.

  22. Vassar R, Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron 2000; 27(3): 419-22. Review.

  23. Wolfe MS, De Los Angeles J, Miller DD, Xia W, Selkoe DJ. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer’s disease. Biochemistry 1999; 38(35): 11223-30. Review.

  24. Jacobsen H, Reinhardt D, Brockhaus M, Bur D, Kocyba C, Kurt H, Grim MG, Baumeister R, Loetscher H. The influence of endoproteolytic processing of familial Alzheimer’s disease presenilin 2 on abeta42 amyloid peptide formation. J Biol Chem 1999; 274(49): 35233-9.

  25. Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem 1994; 269(39): 24290-7.

  26. Mandelkow E, Song YH, Schweers O, Marx A, Mandelkow EM. On the structure of microtubules, tau, and paired helical filaments. Neurobiol Aging 1995; 16(3): 347-54. Review.

  27. Friedhoff P, von Bergen M, Mandelkow EM, Mandelkow E. Structure of tau protein and assembly into paired helical filaments. Biochim Biophys Acta 2000; 1502(1): 122-32. Review.

  28. Goedert M, Ghetti B, Spillantini MG. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann N Y Acad Sci 2000; 920: 74-83. Review.

  29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261(5123): 921-3.

  30. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of polipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43(8): 1467-72.

  31. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92(11): 4725-7. Review.

  32. Davignon J, Little JA, Mahley, 1999 Time to take a stance on cholesterol and lipoproteins. Can J Cardiol 1988; 4(Suppl A): 1A-3A.

  33. Weisgraber KH, Roses AD, Strittmatter WJ. The role of apolipoprotein E in the nervous system. Curr Opin Lipidol 1994; 5(2): 110-6. Review.

  34. Papassotiropoulos A, Lewis HD, Bagli M, Jessen F, Ptok U, Schulte A, Shearman MS, Heun R. Cerebrospinal fluid levels of beta-amyloid(42) in patients with Alzheimer’s disease are related to the exon 2 polymorphism of the cathepsin D gene. Neuroreport 2002; 13(10): 1291-4.

  35. Yanagisawa K, Matsuzaki K. Cholesterol-dependent aggregation of amyloid beta-protein. Ann N Y Acad Sci 2002; 977: 384-6. Review.

  36. Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH. Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J Neurochem 2003; 84(3): 471-9.

  37. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003; 6(4): 345-51. Review.




2020     |     www.medigraphic.com